

AMENDMENTS TO THE CLAIMS

1 - 125. (Canceled).

126. (CURRENTLY AMENDED) A pharmaceutical composition comprising substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate and a pharmaceutically acceptable carrier or diluents.

127. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as containing 2-5% water and 1-5% ethanol by weight in a powder sample.

128. (CURRENTLY AMENDED) The pharmaceutical composition of claim 127, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum comprising at least one peak with chemical shift of about 179.5 ppm.

129. (CURRENTLY AMENDED) The pharmaceutical composition of claim 128, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 178.6 ppm.

130. (CURRENTLY AMENDED) The pharmaceutical composition of claim 129, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid state NMR spectrum further comprising a peak with chemical shifts of about 58.0 ppm.

131. (CURRENTLY AMENDED) The pharmaceutical composition of claim 130, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ^{13}C solid

state NMR spectrum further comprising a peak with chemical shifts of about 17.2 ppm.

132. (CURRENTLY AMENDED) The pharmaceutical composition of claim 131, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ¹³C solid state NMR spectrum further comprising a peak with chemical shifts of about 10.1 ppm.

133. (CURRENTLY AMENDED) The pharmaceutical composition of claim 132, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ¹³C solid state NMR spectrum further comprising a peak with chemical shifts of about 9.8 ppm.

134. (CURRENTLY AMENDED) The pharmaceutical composition of claim 133, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ¹³C solid state NMR spectrum further comprising a peak with chemical shifts of about 9.3 ppm.

135. (CURRENTLY AMENDED) The pharmaceutical composition of claim 134, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ¹³C solid state NMR spectrum further comprising a peak with chemical shifts of about 7.9 ppm.

136. (CURRENTLY AMENDED) The pharmaceutical composition of claim 135, wherein said substantially pure ~~Form F~~ crystalline azithromycin monohydrate hemi-ethanol solvate is characterized as having a ¹³C solid state NMR spectrum further comprising a peak with chemical shifts of about 6.6 ppm.

137. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126,
wherein said substantially pure Form F crystalline azithromycin
monohydrate hemi-ethanol solvate comprises 82% or more by weight of
form F azithromycin crystalline azithromycin monohydrate hemi-ethanol
solvate.

138. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126,
wherein said substantially pure Form F crystalline azithromycin
monohydrate hemi-ethanol solvate comprises 84% or more by weight of
form F azithromycin crystalline azithromycin monohydrate hemi-ethanol
solvate.

139. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126,
wherein said substantially pure Form F crystalline azithromycin
monohydrate hemi-ethanol solvate comprises 86% or more by weight of
form F azithromycin crystalline azithromycin monohydrate hemi-ethanol
solvate.

140. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126,
wherein said substantially pure Form F crystalline azithromycin
monohydrate hemi-ethanol solvate comprises 88% or more by weight of
form F azithromycin crystalline azithromycin monohydrate hemi-ethanol
solvate.

141. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126,
wherein said substantially pure Form F crystalline azithromycin
monohydrate hemi-ethanol solvate comprises 90% or more by weight of
form F azithromycin crystalline azithromycin monohydrate hemi-ethanol
solvate.

142. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126,
wherein said substantially pure Form F crystalline azithromycin
monohydrate hemi-ethanol solvate comprises 94% or more by weight of

~~form F azithromycin crystalline azithromycin monohydrate hemi-ethanol solvate.~~

143. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126, wherein said substantially pure ~~Form F crystalline azithromycin monohydrate hemi-ethanol solvate~~ comprises 96% or more by weight of ~~form F azithromycin crystalline azithromycin monohydrate hemi-ethanol solvate.~~

144. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126, wherein said substantially pure ~~Form F crystalline azithromycin monohydrate hemi-ethanol solvate~~ comprises 98% or more by weight of ~~form F azithromycin crystalline azithromycin monohydrate hemi-ethanol solvate.~~

145. (CURRENTLY AMENDED) The pharmaceutical composition of claim 126, wherein said substantially pure ~~Form F crystalline azithromycin monohydrate hemi-ethanol solvate~~ comprises 99% or more by weight of ~~form F azithromycin crystalline azithromycin monohydrate hemi-ethanol solvate.~~